Testing new drug combo for HER2-positive bile duct and gallbladder cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of targeted therapies for people with advanced bile duct or gallbladder cancer that has not been treated before and shows a specific protein called HER2. The goal is to see if the combination shrinks tumors and slows the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic bile duct or gallbladder cancer that has not yet been treated with systemic therapy.
- Your cancer has a protein called HER2, measured as strong (3+) or moderate with positive gene test.
- You are in good enough health to walk and care for yourself (ECOG 0 or 1).
- Your organs (kidneys, liver, bone marrow) work well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) as a first treatment for people with advanced HER2-positive or HER2-low bile duct or gallbladder cancer. The goal is to see if this combination helps shrink or control the cancer.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combo—disitamab vedotin, lenvatinib, and an immunotherapy—for people with advanced bile duct cancer that has HER2 protein. It aims to see if this combination can shrink tumors or slow the disease.
This trial tests a new combination of two drugs (T-DXd and rilvegostomig) for people with advanced bile duct cancer that has not been treated before. The cancer must have high levels of a protein called HER2. This study compares the new drugs to standard treatments.
Hear when a new First Line Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.